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Summary 
This systematic review indicates that the evidence to use APPs and IP-10 as triage markers for TB 
is encouraging, but further prospective studies are needed to establish adequate cut offs for triage 
purposes and the additional value of using a combination of these markers. 
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Abstract 
Objectives 
We examined the data reported in studies for diagnostic purposes and discuss whether their 
intended use could be extended to triage, as rule in or rule out tests to select individuals who 
should undergo further confirmatory tests. 
Methods 
We searched SCOPUS, PubMed and Web of Science with the terms “acute-phase-proteins”, “IP-
10”, “tuberculosis”, “screening” and “diagnosis”, extracted the sensitivity and specificity of the 
biomarkers and explored methodological differences to explain performance variations. Summary 
estimates were calculated using random-effects models for overall pooled accuracy. Hierarchical 
Summary Receiver Operating Characteristic (HSROC) model was used for meta-analysis. 
Results 
We identified 14, four and one studies for C-reactive protein (C-RP), Interferon-γ-induced-
protein-10 (IP-10) and α-1-acid glycoprotein (A1AG). The pooled C-RP sensitivity/specificity 
(95%CI) was 89% (80%-96%) and 57% (36%-65%). Sensitivity/specificity were higher in high 
TB-burden countries (90%/64%), HIV-infected individuals (91%/61%) and community-based 
studies (90%/62%). IP-10 sensitivity/specificity in TB vs Non-TB studies was 85%/63% and in TB 
and HIV co-infected vs other lung conditions 94%/21%. However, IP-10 studies included diverse 
populations and a high risk of bias resulting in very low quality evidence. A1AG had 86%/93% 
sensitivity/specificity. 
Conclusion 
Few studies have evaluated C-RP, IP-10 and A1AG for the triage of symptomatic patients. Their 
high sensitivity and moderate specificity warrant further prospective studies exploring whether 
their combined use could optimise performance.  
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Introduction 
Tuberculosis (TB) causes an estimated 1.7 million deaths and 10.4 million incident cases per year 
[1]. Despite its public health burden, nearly one third of the estimated cases are missed by 
national surveillance systems, suggesting that many cases fail to reach the health services.  TB 
mortality is higher in patients with a late diagnosis, advanced disease stages and co-infection with 
HIV, and strategies which increase case detection and reach an early diagnosis are integral to the 
global strategy for the control of TB [2]. 
One of the major problems for the management of TB is the inefficiency of the diagnostic cascade. 
Diagnostic investigations are usually triggered after a patient has had cough for two or more 
weeks and the tests used are unsuitable for rapid and large-scale screening. The most frequently 
used tests, smear microscopy and Xpert MTB/RIF, are highly specific. However, smear 
microscopy has low sensitivity and is technically unsuitable as a screening tool, and Xpert 
MTB/RIF and X-Rays require an infrastructure that is rarely available at peripheral diagnostic 
centres.  It is recognised that diagnostic algorithms could be improved with the use of triage tests 
that select patients requiring further confirmatory tests and exclude patients unlikely to have TB 
[3]. The World Health Organization has included, among the high priority target product profiles 
(TPP) for TB diagnosis, a non-sputum-based triage test, which, under ideal conditions, would 
require sensitivity ≥95% and specificity >75% [4]. However, early promising prototypes for triage, 
such as a Beta Lactamase C assay [5], failed to reach the production stages and the pipeline for 
these tests has very few candidates [6]. 
Serum levels of acute phase proteins (APPs) and cytokines are increased in individuals with TB.  
Among these, C-reactive protein (C-RP) is often used in clinical practise as an adjuvant test for 
diagnosis (especially in children) [7] and interferon gamma-induced protein 10 (IP-10) may have 
potential to monitor treatment responses to anti-TB therapy [7–9]. Despite their frequent use for 
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diagnosis, they are rarely used as triage tests and their use for these different purposes require 
different performance characteristics. Cut offs or thresholds for a test for diagnostic purposes are 
defined to achieve a high accuracy and use the best combination of sensitivity and specificity 
whereas triage tests require high sensitivity, to identify as many cases as possible, often at the 
expense of lower specificity.   
There is renewed interest to explore whether APPs and cytokines could be used as triage tests for 
TB. As few studies have considered using APPs and IP-10 for screening purposes, we examined 
the data reported in studies for diagnostic purposes and discuss whether their intended use could 
be extended to triage, as rule in or rule out tests to select individuals who should undergo further 
confirmatory tests. 
Methods 
This study was conducted following the Cochrane Collaboration’s Diagnosis Test Accuracy 
Working Group protocol. Institutional review board approval and informed consent was not 
required for this systematic review and meta-analysis. A study protocol was designed a priori and 
was registered in the PROSPERO database (registration number CRD42018087015). We reported 
our findings according to Preferred Reporting Items for Systematic Reviews and Meta-Analysis 
(PRISMA) guidelines. 
Search strategy and selection criteria 
We performed a systematic review using SCOPUS, PubMed and Web of Science databases to 
identify studies published without language restriction up to October 14, 2017. We used the 
search terms “acute phase proteins”, “IP-10”, “tuberculosis”, “screening”, “diagnosis” and related 
terms. The full search strategy is described in the Appendix. Two independent review authors 
(VSS and KK) screened the title and abstract for relevance and a third review author (LEC) was 
consulted to resolve disagreements. Articles considered to have original material were obtained 
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and assessed in detail and the references cited in these publications were searched to identify 
further publications.  
We included studies that met the following conditions: (1) The study used quantitative 
laboratory-based and/or point-of-care assays to measure levels of at least one of APP (Alpha 1-
antichymotrypsin, Alpha 1-antitrypsin, Alpha 2-macroglobulin, Alpha-1-acid glycoprotein, 
Ceruloplasmin, Complement factors, C-reactive protein, Factor VIII, Ferritin, Fibrinogen, 
Haptoglobin, Hepcidin, Mannan-binding lectin, Orosomucoid, Plasminogen activator inhibitor 
PAI-1, Prothrombin, Serum amyloid A, Serum amyloid P component and von Willebrand factor), 
or unstimulated IP-10 as an index test. We included unstimulated IP-10 because there is an 
extensive number of publications reporting its potential use for diagnosis. (2) The study enrolled 
symptomatic patients suspected of active pulmonary TB, and who ended up a proportion was 
confirmed as having PTB and another proportion as having other lung disease. (3) Cases had 
confirmed pulmonary tuberculosis based on solid and/or liquid sputum M. tuberculosis culture as 
the reference standard. (4) It reported cases in absolute numbers of true-positive, false- positive, 
false-negative, and true-negative results, or these data were derivable from the published results. 
Articles were included regardless of age (adults or children) or if they had co-infections (e.g. 
HIV).  
We excluded studies that only reported stimulated IP-10 values, but the authors of these studies 
were asked to provide the non-stimulated baseline results if available (e.g. the Nil values of the 
Quantiferon assay) to prepare additional Receiver Operating Curves (ROC) for meta-analysis. 
Studies that focused on latent Mycobacterial tuberculosis infections, those who tested patients 
after initiation of treatment and those that used samples other than blood (e.g. pulmonary biopsies 
or pleural exudates) and case-control studies were excluded.  
Data extraction and bias assessment 
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We predefined tables for data extraction, which were piloted in 10 articles. The information 
extracted included author, country, study design, clinical setting (hospital or community) 
participant characteristics, case definition for TB diagnosis, markers included, method of 
detection and the threshold used for each marker. We extracted the absolute numbers of true-
positive, false-positive, false-negative and true-negative test results from the paper or through 
(re)calculations of the sensitivity and specificity based on the authors’ diagnostic classification of 
the participants and sample size of the study. If a study presented multiple cut-off values for an 
index test and, as consequence, reported multiple pairs of sensitivity and specificity, the data with 
the best combined estimates for sensitivity and specificity were extracted. Countries were 
classified as per the World Health Organization Burden of TB classification (WHO classification) 
[1] to describe the epidemiological context. The quality of studies and the risk of bias were 
assessed by two independent reviewer authors using the QUADAS-2 guidelines as shown in the 
Material Supplementary. We used the RevMan software (version 5.3; Cochrane Collaboration) to 
generate the graphs on the risk of bias. 
Statistical analysis 
We used the sensitivity and specificity of the markers reported by the author or (re)calculated 
them from the data presented. For diagnostic performance of C-RP, we fitted the Hierarchical 
Summary Receiver Operating Characteristic (HSROC) model proposed by Rutter and Gatsonis 
[10], which take into account correlation between sensitivity and specificity across studies while 
also allowing for variation in test performance between studies through the inclusion of random 
effects. We expected that the methods for measuring the markers and the cut-offs would vary 
across studies, and thus investigated potential methodological and assay differences to interpret 
variations in performance. An exploratory analysis to investigate potential factors of 
heterogeneity was performed by visual inspection of HSROC curves. Meta-regression was 
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conducted by adding these factors as covariates to the hierarchical model [11]. The characteristics 
explored were the WHO TB burden classification of the country where the study took place 
(high-burden vs others), HIV status (positive vs negative), clinical settings (hospitalized vs 
community) and method for C-RP quantification. Publication bias was examined using the 
effective sample size funnel plot and associated regression test of asymmetry described by Deeks 
and colleagues [12]. 
For IP-10, as few studies were available, the diagnostic performance was analysed by modelling 
the trade-off between sensitivity and specificity using the Moses SROC regression 
[13,14].  
For all analyses Two-sided p < 0.05 values were considered statistically significant. Statistical 
analyses were performed using the R statistical programming language (version 2.10.13; R Core 
Team, 2013) and STATA (version 14; Stata Corp LP).  
Role of the funding source 
The funder of the study had no role in study design, data collection, data analysis, data 
interpretation, or writing of the article. 
Results 
The search strategy identified 891 records. After screening titles and abstracts, 104 full-text 
articles were assessed for eligibility and 19 were included (Figure 1). C-RP was reported in 14 
studies [15–28], IP-10 in four [29–32] and alpha-1-acid glycoprotein[33] in one. Table 1 
summarize the main characteristics of each study. 
C-reactive protein  
Six of the 14 studies reporting C-RP sensitivity and specificity included only HIV-infected 
individuals [16,19,24,26–28], four only HIV-uninfected [17,21,23,25], two both HIV-infected and 
HIV-uninfected patients [20,22] and in two studies the HIV status was not described [15,18]. Nine 
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studies were conducted in high TB burden countries [15,16,20,22,24–28]. Nine studies enrolled 
patients in community settings [15,17,18,22,24–28], five enrolled hospitalized patients [16,19–
21,23]. All studies focused on adults. Most studies used a 10 mg/dl cut-off point (Table 1). 
The quality of the studies and the risk of bias are shown in appendix (see Supplementary eFigures 
1 and 2). The QUADAS-2 tool showed that the studies that enrolled patients in the community 
had a lower risk of bias than studies enrolling hospitalized patients. Most studies enrolling 
community individuals were designed to evaluate the diagnostic accuracy of C-RP for TB and 
enrolled a representative spectrum of patients, whereas hospital studies did not provide sufficient 
information to determine the patient selection method and unclear blinding for the interpretation 
of results, which are potential sources of bias. 
The overall (95%CI) pooled sensitivity of C-RP was 89% (80%-96%) with a pooled (95%CI) 
specificity of 57% (36%-65%) (Table 2). The positive and negative likelihood ratio (95%CI) was 
1.91 (1.42-2.56) and 0.21 (0.10-0.43), respectively (See Supplementary eTable 1 and 2). The 
summary dOR (95%CI) was 8.27 (3.40-20.00) (See Supplementary eTable 3). The HSROC curve 
for C-RP is shown in Figure 2. Table 3 describes the sub-group analysis. C-RP had a higher pooled 
sensitivity and specificity (95%CI) in countries with high TB burden (90% [82%-92%] and 64% 
[53%-75%]), in HIV-infected patients (91% [85%-93%] and 61% [32%-71%]), and in community 
patients (90% [85%-93%] and 62% [51%-73%], respectively). 
To investigate the potential sources for heterogeneity, we conducted a meta-regression analysis 
using the country TB burden, HIV status, clinical settings and C-RP assays. Of these, the most 
important source of heterogeneity was the clinical setting (Table 4). We also explored the 
performance for C-RP among HIV-infected patients from high TB burden countries. The pooled 
(95%CI) sensitivity for this group was 92% (89%-94%), with a pooled (95%CI) specificity of 66% 
(64%-68%).  
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No publication bias and high symmetry of the included studies were proved by Deeks’ funnel 
plot asymmetry test (P = 0.73; Figure 3). 
IP-10  
Unstimulated IP-10 values were obtained from four studies [29–32] (Table 1). One studies 
included HIV-uninfected individuals [29], two included both HIV-uninfected and HIV-infected 
patients [30,32] and in one the HIV status was unknown[31]. Three studies[29–31]  were 
conducted in adults and only one in children [32]. All studies used culture positive from sputum 
as the reference standard for the confirmation of cases. There was a wide variation in the kits and 
thresholds used, and many studies did not report the cut-offs selected, which precluded further 
analysis. 
Most of the studies did not enrol a representative spectrum of patients or failed to provide 
satisfactory information to determine the patient selection methods. Furthermore, the unblinded 
interpretation of results, the lack of a pre-specified cut-off thresholds and the different assays used 
were common sources of potential bias (See Supplementary Figures 6 and 7). 
As the studies included a wide range of populations (often without matched groups), it was not 
possible to estimate pooled sensitivity and specificity across the studies. The performance of 
unstimulated IP-10 test is thus presented for each group in Table 5. The pooled (95%CI) 
sensitivity and specificity to diagnose TB was 85% (77%-92%) and 63% (54%-71%), respectively. 
Studies comparing patients with TB and HIV co-infection and patients with other lung diseases 
had an estimated sensitivity of 94% (80%-99%) and specificity of 21% (14%-29%). Summary 
diagnostic Odds Ratio (dOR): TB vs Non-TB, 13.19 (95% 2.28 to 76.27); TB HIV+ vs Non-TB 
HIV+, 3.11 (95% 0.79 to 12.26). 
Alpha-1-acid glycoprotein 
Only one study[33] reported data for alpha-1-acid glycoprotein was included. This study enrolled 
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21 patients with TB and 27 patients with bacterial pneumonia. The sensitivity and specificity 
(95%CI) were 86% (64%-95%) and 93% (75%-98%), respectively. 
There were no studies describing the combined use of C-RP with IP-10 or Alpha-1-acid 
glycoprotein to explore whether using two or more of these markers would result in a higher 
sensitivity. 
Discussion 
It is estimated that nearly 4.1 million TB cases are missed annually worldwide[1] and increasing 
the accessibility of diagnostic and treatment services is essential for its effective control. Although 
sensitive and specific molecular diagnostics, such as Xpert MTB/RIF, are now available, these tests 
require well-established laboratory facilities and are relatively expensive for low income 
countries. Although National Programs are attempting to increase the use Xpert MTB/RIF as the 
first test for diagnosis of presumptive TB, patients attending primary health centres are mostly 
screened using smear microscopy or need to travel, or have their samples transported, to 
laboratories with Xpert MTB/RIF facilities.  The goal of an accessible and efficient quality 
diagnosis therefore remains elusive and is one of the largest stumbling barriers for TB control.  
Improved diagnostic algorithms able to triage patients to select individuals with a high or low 
probability of TB could optimise the use of limited resources of national programs. These 
approaches should be able to identify (rule in) individuals with a high risk of TB and rule out 
those who, despite their symptoms, have a low likelihood of TB. Triage approaches also need to 
be simple and rapid, without the need of complex platforms to facilitate implementation in low 
resource settings.  
Here we reviewed the potential of established APPs currently used as adjunct assays for the 
diagnosis of TB. APPs are proteins whose plasma concentrations increase or decrease rapidly as an 
innate response to injury or local inflammation. C-RP for example, binds to bacterial and fungal 
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cell walls and to phosphocholine in the surface of damaged human cells and a high concentration 
suggests the presence of bacterial infections. Although their stimulation in response to a wide 
range of inflammatory processes would result in a low specificity, their high sensitivity and the 
maintenance of response integrity even in individuals with young age or the immunodeficiency 
of severe malnutrition and HIV, have resulted in their frequent use for the diagnosis and 
management of infection.  Paradoxically, although APPs are included in many diagnostic 
algorithms for TB, especially in children, these markers are usually used in parallel with other 
tests and testing is rarely reported in a step-wise cascade for triage.  This is a major limitation, as 
markers used for diagnosis are used in parallel with other tests, while screening tests are usually 
cascaded, with an emphasis on high sensitivity for selection of patients who should undergo more 
specific tests for confirmation.   
The screening of TB among HIV-infected individuals is also particularly challenging. A recent 
systematic review of C-RP for the screening of TB in patients with HIV however, reported 
unexpectedly good results in this high-risk group [34].  
Furthermore, although many studies have investigated IP-10 expression as a specific response to 
the in-vitro stimulation of white blood cells to specific TB antigens, few studies have reported its 
use in its steady – unstimulated – concentrations. Altered serum and/or tissue expression of IP-10 
has been associated with inflammatory diseases, including organ-specific or systemic autoimmune 
diseases [35], neurological disorders [36], vascular diseases [37,38], and viral and bacterial 
infections [39]. One previous meta-analysis [40] reported a pooled sensitivity and specificity of 
73% and 82% for the diagnosis of TB. However, this study included data of both stimulated and 
unstimulated IP-10, patients with pleural effusions and compared patients with TB and healthy 
controls, which limited its interpretation. In the current study, we focused on non-stimulated (in 
the absence of in vitro TB antigens) IP-10 in patients with pulmonary TB and requested datasets 
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from investigators to conduct a reanalysis with a triage perspective. Although the number of 
studies is small, C-RP and IP-10 seem to have high sensitivity and moderate specificity as triage 
markers in patients with symptoms suggestive of active TB.  Our data resulted in a C-RP pooled 
sensitivity and specificity of 89% and 57%, while the pooled sensitivity and specificity for IP-10 
were 85% and 63%. Despite their low/moderate specificity, these performances would make them 
strong candidates for triage because, although they miss the TPP targets, their performance could 
potentially be improved by calculating optimal screening cut-offs in prospectively enrolled 
patients. Several semi-quantitative C-RP tests are also available in the market and their use as 
point of care devices for screening would increase the capacity of the health services to diagnose 
larger number of patients. IP-10 studies in turn, were judged to have a high risk of bias and high 
concern about applicability. Furthermore, the IP-10 studies included were considered to have a 
high risk of bias and thus the quality of evidence is very low at this stage.   
Our findings therefore should be treated with caution as we faced important limitations. As 
expected, the performance of the markers varied with the burden of TB across settings, with a 
higher sensitivity and specificity in high burden countries. The higher sensitivity in these settings 
may reflect the late presentation of patients to health services and the higher frequency of co-
morbidities, such as HIV, malaria and bacterial co-infections.  The higher specificity may reflect 
the location used to enrol study participants, as most studies were based on TB diagnostic services, 
where the proportion of patients with TB would be higher than in general clinical services.  Some 
studies also did not provide sufficient information to determine the patient selection method, 
with unclear blinding and some studies used inappropriate patient exclusions with potential to 
introduce bias. Furthermore, although there was no limitation in the search for children, most the 
articles limited their analyses to adults, which fixed the interpretations of our findings to this age 
group. As much as possible, data included comparisons between patients with and without a 
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diagnosis of TB.  Our findings therefore reflect the investigator-selected cut-offs, usually decided 
retrospectively by observing the data, which limited our ability to establish an appropriate 
threshold for screening across the studies. Other APPs, such as Alpha-1-acid glycoprotein should 
also be explored.  Although this biomarker could have similar potential as C-RP for triage, we 
could only find one publication that met the inclusion criteria.   
The results of these studies can be modelled in an scenario where C-RP assays were to be used in 
a high TB prevalence setting in a group of 1000 individuals with symptoms compatible with TB, 
where 200 (20%) are typically expected to have a positive TB culture (confirmed TB). In this 
scenario, the C-RP test would be followed by a confirmatory test (e.g. Xpert MTB/RIF) with an 
estimated 75% sensitivity and 98% specificity.  In this scenario, an estimated 468 participants will 
have a positive C-RP result [180 true and 288 false positive) and 562 would have negative C-RP 
(512 true and 50 false negative). The follow on Xpert test among the 468 patients with positive C-
RP would correctly identify 135 patients with confirmed TB and 6 patients with false positive 
results.  The combination of C-RP followed by Xpert would then yield 926 (92.6%) patients 
correctly classified, of which 135 would have confirmed TB and 794 would not have confirmed 
TB (negative culture). In contrast, testing the same population with the routine Xpert MTB/RIF as 
the first test would result in 150/200 patients with TB being classified as having TB and 784/800 
participants correctly classified as not having TB (culture negative.  This would result in 934 
(93.4%) patients correctly classified, of which 150 would have confirmed TB and 784 not to have 
confirmed TB (negative culture). Although the difference between the two approaches is not 
statistically significant, the screening test would result in significant gains by rapidly identifying 
562 patients with a very low likelihood of having TB, facilitating earlier clinical management 
decisions and avoiding having to wait for Xpert test results and multiple visits. 
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Further prospective studies are needed to establish the optimal assays and thresholds for C-RP 
and/or unstimulated IP-10 for TB screening, and whether their combined use could increase their 
performance. Future studies should enrol prospectively consecutive patients with signs and 
symptoms of presumptive TB undergoing a differential diagnosis. In conclusion, C-RP is a 
promising marker as a triage test to identify individuals with TB, while the evidence available for 
IP-10 is of very low quality and and further prospective studies are warranted for both markers.   
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Figure legend 
 
Figure 1. Flow diagram of study selection. 
Figure 2. Diagnostic accuracy of C-reactive protein test. 
Figure 3. Deeks’ funnel plot to analyze the likelihood of publication bias. 
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Table 1. Characteristic of the studies included. 
Study Country 
Study 
design 
Status HIV Setting Study subjects Tuberculosis definition Non-TB definition Detection method Threshold 
Alpha-1-acid glycoprotein         
Fassbender, 1995 Germany 
Cross 
sectional 
Unknown Community 
21 confirmed TB, 
27 non-TB and 36 
healthy controls. 
Confirmed TB based on 
positive culture from 
sputum. 
Non-TB patients: sick 
adults who were initially 
suspected of PTB, but who 
ended up had other 
disease. 
Immuno-
electrophoresis 
(immunoaffinity) 
Not provided 
C-Reactive protein         
Lin, 1986 China 
Cross 
sectional 
Unknown Community 
18 confirmed TB, 
26 non-TB, 12 
healed TB and 31 
healthy controls.  
Confirmed TB based on 
clinical features, X-ray of 
chest, smear or culture 
from sputum 
Non-TB patients: sick 
adults who were initially 
suspected of PTB, but who 
ended up had other 
disease. 
 
Nephelometry 7 µg/mL 
Wilson, 2006 
South 
Africa 
Cohort Positive Hospital 
59 confirmed TB 
and 15 non-TB 
patients 
Confirmed TB based on 
positive culture from 
sputum. 
Non-TB patients: adults 
who were initially 
suspected of active TB, but 
who ended up had other 
disease. 
Immuno-
turbidimetry 
10 mg/L 
Choi, 2007 
South 
Korea 
Cross 
sectional 
Negative Community 
46 confirmed TB 
and 67 non-TB 
patients. 
Confirmed TB based on 
positive culture from 
sputum. 
Non-TB patients: sick 
adults who were initially 
suspected of PTB, but who 
ended up had other 
disease. 
Immuno-
turbidimetry 
11.2 mg/L 
Kang, 2009 
South 
Korea 
Prospectiv
e study 
Unknown Community 
30 confirmed TB 
and 57 non-TB 
patients. 
Confirmed TB based on 
positive culture from 
sputum. 
Non-TB patients: sick 
adults who were initially 
suspected of PTB, but who 
ended up had other 
disease. 
Immuno-
turbidimetry 
12.5 mg/L 
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Sage, 2010 
United 
Kingdom 
Prospectiv
e study 
Positive Hospital 
28 confirmed TB 
and 219 non-TB 
patients. 
Confirmed TB based on 
positive culture from 
sputum. 
Non-TB patients: sick 
adults who were initially 
suspected of PTB, but who 
ended up had other 
disease. 
ELISA 10 mg/L 
Bandyopadhyay, 
2011 
India Cohort 
Negative/p
ositive 
Hospital 
9 confirmed TB 
and 43 non-TB 
patients. 
Confirmed TB based on 
positive culture from 
sputum. 
Non-TB patients: sick 
adults who were initially 
suspected of PTB, but who 
ended up had other 
disease. 
Immuno-
turbidimetry 
10 mg/L 
Lee, 2011 
South 
Korea 
Prospectiv
e study 
Negative Hospital 
82 confirmed TB 
and 190 non-TB 
patients. 
Confirmed TB based on 
positive culture from 
sputum. 
Non-TB patients: sick 
adults who were initially 
suspected of PTB, but who 
ended up had other 
disease. 
Immuno-
turbidimetry 
10 mg/L 
Wilson, 2011 
South 
Africa 
Prospectiv
e study 
Negative/p
ositive 
Community 
135 confirmed TB 
and 115 non-TB 
patients. 
Confirmed TB based on 
positive culture from 
sputum. 
Non-TB patients: adults 
who were initially 
suspected of active TB, but 
who ended up had other 
disease. 
immunoturbidime
try/ 
spectrophotometr
y 
10 mg/L 
Cho, 2012 
South 
Korea 
Prospectiv
e study 
Negative Hospital 
40 confirmed TB 
and 33 non-TB 
patients. 
Confirmed TB based on 
positive culture from 
sputum. 
Non-TB patients: sick 
adults who were initially 
suspected of PTB, but who 
ended up had other 
disease. 
Immuno-
turbidimetry 
10 mg/L 
Lawn, 2013 
South 
Africa 
Cohort Positive Community 
81 confirmed TB 
and 415 non-TB 
patients. 
Confirmed TB based on 
positive culture from 
sputum. 
Non-TB patients: sick 
adults who were initially 
suspected of PTB, but who 
ended up had other 
disease. 
ELISA 5 mg/L 
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Niu, 2013 China 
Cross 
sectional 
Negative Community 
78 confirmed TB 
and 113 non-TB 
patients 
Confirmed TB based on 
positive culture from 
sputum. 
Non-TB patients: sick 
adults who were initially 
suspected of PTB, but who 
ended up had other 
disease. 
immune scatter 
turbidimetry 
15.2 mg/mL 
Drain, 2014 
South 
Africa 
Prospectiv
e study 
Positive Community 
45 confirmed TB 
and 47 non-TB 
patients 
Confirmed TB based on 
positive culture from 
sputum. 
Non-TB patients: sick 
adults who were initially 
suspected of PTB, but who 
ended up not having TB. 
Immunometric 
semi-quantitative 
assay/ 
spectrophotometr
y 
8 mg/L 
Yoon, 2014 Uganda 
Prospectiv
e study 
Positive Community 
27 confirmed TB 
and 244 non-TB 
patients 
Confirmed TB based on 
positive culture from 
sputum. 
Non-TB patients: sick 
adults who were initially 
suspected of PTB, but who 
ended up not having TB. 
ELISA 10 mg/L 
Yoon, 2017 Uganda 
Prospectiv
e study 
Positive Community 
163 confirmed TB 
and 1014 non-TB 
patients 
Confirmed TB based on 
positive culture from 
sputum. 
Non-TB patients: sick 
adults who were initially 
suspected of PTB, but who 
ended up not having TB. 
ELISA 10 mg/L 
IP-10          
Hong, 2012 
South 
Korea 
Cross 
sectional 
Negative 
Hospital/com
munity 
46 confirmed TB, 
22 LTBI and 32 
health controls. 
Confirmed TB based on 
positive culture from 
sputum. 
Non-TB patients: sick 
adults who were initially 
suspected of PTB, but who 
ended up had other 
disease. 
ELISA 119 pg/ml 
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Vanini, 2012 Italy 
Prospectiv
e study 
Negative/p
ositive 
 
Community 
58 confirmed TB 
and 137 Non-TB 
patients. 
Confirmed TB based on 
positive culture from 
sputum. 
Non-TB patients: sick 
adults who were initially 
suspected of PTB, but who 
ended up had other 
disease. 
ELISA Not provided 
Yang, 2014 China 
Cross 
sectional 
Unknown 
Hospital/com
munity 
123 confirmed TB 
patients, 91 non-
TB patients, 33 
LTBI patients and 
36 health 
controls. 
Confirmed TB based on 
positive culture from 
sputum. 
Non-TB patients: sick 
adults who were initially 
suspected of active TB, but 
who ended up had but 
other disease.  
ELISA Not provided 
Petrone, 2015 Uganda 
Cross 
sectional 
Negative/p
ositive 
Hospital/com
munity 
32 confirmed TB 
patients, 79 non-
TB patients 
Confirmed TB based on 
positive culture from 
sputum. 
Non-TB patients: sick 
children who were 
initially suspected of PTB, 
but who ended up had 
other disease. 
ELISA 209.1 pg/mL 
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Table 2. Diagnostic performance of C-Reactive protein for the diagnosis of TB 
 Test result, Number of patients 
Source True-positive False-positive False-negative True-negative Sensitivity (95%CI) 
Specificity 
(95%CI) 
Lin, 1986 15 6 3 20 89% (65%-99%) 77% (57%-91%) 
Wilson, 2006 57 10 2 5 97% (88%-100%) 33% (12%-62%) 
Choi, 2007 44 39 2 28 96% (85%-99%) 42% (30%-54%) 
Kang, 2009 30 28 0 29 100% (88%-100%) 51% (37%-64%) 
Sage, 2010 25 171 3 48 89% (72%-98%) 22% (17%-28%) 
Bandyopadhyay, 2011 5 14 4 29 56% (21%-86%) 67% (51%-81%) 
Lee, 2011 67 175 15 15 82% (72%-89%) 8% (4%-13%) 
Wilson, 2011 128 27 7 88 95% (90%-98%) 77% (68%-84%) 
Cho, 2012 23 20 17 13 58% (41%-73%) 39% (23%-58%) 
Lawn, 2013 73 233 8 182 90% (81%-96%) 44% (39%-49%) 
Niu, 2013 64 14 14 21 82% (72%-90%) 60% (42%-76%) 
Drain, 2014 44 22 1 26 98% (88%-100%) 54% (39%-69%) 
Yoon, 2014 22 47 5 197 81% (62%-94%) 81% (75%-85%) 
Yoon, 2017 145 283 18 731 89% (83%-93%) 72% (69%-75%) 
Summary estimates - - - - 89% (80%-96%) 57% (36%-65%) 
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Table 3. Sub-group analysis for diagnosis performance of C-Reactive protein for the diagnosis of 
TB 
Subgroups Number of studies Sensitivity (95%CI) Specificity (95%CI) 
    
TB burden    
  High-burden countries  9 90% (82%-92%) 64% (53%-75%) 
  Other countries 5 86% (69%-81%) 28% (15%-48%) 
HIV-status    
  Unknown 2 90% (54%-99%) 63% (36%-85%) 
  HIV-infected 6 91% (85%-93%) 61% (32%-71%) 
  HIV-uninfected 4 81% (65%-90%) 32% (12%-63%) 
  HIV uninfected/infected 2 83%(27%-98%) 73% (65%-81%) 
Clinical setting    
  Community  9 90% (85%-93%) 62% (51%-73%) 
  Hospital 5 80% (61%-91%) 51% (37%-64%) 
C-RP quantification method    
  Nephelometry 1 83% (59%-95%) 77% (57%-89%) 
  Immunoturbidimetry 9 88% (78%-94%) 46% (29%-65%) 
  ELISA 4 88% (84%-91%) 55% (31%-77%) 
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Table 4. Meta-regression analysis for potential sources of heterogeneity.   
Variable Sensitivity Specificity 
 Coefficient (95%CI) Std. error P-value Coefficient (95%CI)  Std. error P-Value 
WHO TB burden       
High-burden country reference      
Other country 1.686 (0.140 to 3.232) 0.789  0.033  -0.750 (-2.104 to 0.605) 0.691  0.278  
HIV status       
Unknown reference      
HIV uninfected -1.020 (-4.171 to 2.132) 1.608  0.526  -0.366 (-1.841 to 1.110) 0.753  0.627  
HIV infected 1.360 (-2.414 to 5.134) 1.926  0.480  -0.617 (-2.641 to 1.407) 1.033  0.550  
HIV uninfected/infected -0.127 (-4.428 to 4.173 )  2.194  0.954  1.149 (-1.748 to 4.046) 1.478  0.437  
Clinical setting       
Community reference      
Hospital -2.074 (-3.574 to -0.574) 0.765  0.007 -1.205 (-2.455 to 0.045) 0.638  0.059  
Community/Hospital -0.434 (-2.890 to 2.022) 1.253  0.729 -0.860 (-2.635 to 0.915) 0.906  0.342  
C-RP quantification method       
Nephelometry reference      
ELISA -0.899 (-4.905 to 3.107) 2.044  0.660  0.107 (-2.399 to 2.613) 1.279  0.933  
Immuno-turbidimetry 0.815 (-2.627 to 4.258) 1.756  0.643  -0.420 (-2.566 to 1.727) 1.095  0.702  
Intercept 1.609 (0.347 to 2.872) 0.644  0.012 1.204 (-0.088 to 2.496) 0.659  0.068  
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Table 5. Diagnostic performance of IP-10 for the diagnosis of TB 
 Test result, Number of patients 
Source True-positive False-positive False-negative True-negative Sensitivity 
(95%CI) 
Specificity 
(95%CI) 
TB vs Non-TB       
Hong, 2012 21 10 3 12 0.88 (0.67-0.95) 0.55 (0.34-0.73) 
Yang, 2014 41 3 5 30 0.89 (0.81-0.95) 0.91 (0.75-0.97) 
Petrone, 2015 25 37 7 42 0.78 (0.61-0.89) 0.53 (0.43-0.64) 
Summary estimates - - - - 0.85 (0.77-0.92) 0.63 (0.54-0.71) 
TB HIV+ vs Non-TB HIV+       
Vanini, 2012 19 76 2 21 0.91 (0.69-0.98) 0.22 (0.15-0.31) 
Petrone, 2015 13 15 0 3 0.96 (0.62-0.99) 0.20 (0.07-0.42) 
Summary estimates - - - - 0.94 (0.80-0.99) 0.21 (0.14-0.29) 
 
 
  
  33 
 
  34 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  35 
 
 
 
  
  36 
Supplementary appendix 
 
Search strategy PubMed 
 
Search Query 
Items 
found 
#1 
((("acute-phase proteins"[MeSH Terms] OR ("acute-phase"[All Fields] AND 
"proteins"[All Fields]) OR "acute-phase proteins"[All Fields] OR ("acute"[All 
Fields] AND "phase"[All Fields] AND "protein"[All Fields]) OR "acute phase 
protein"[All Fields]) OR IP-10[All Fields]) AND ("tuberculosis"[MeSH Terms] OR 
"tuberculosis"[All Fields])) AND ("diagnosis"[Subheading] OR "diagnosis"[All 
Fields] OR "diagnosis"[MeSH Terms]) AND "humans"[MeSH Terms] 
532 
 
Search strategy SCOPUS 
Search Query 
Items 
found 
#1 
acute phase proteins OR (IP-10)) AND (tuberculosis) AND ((Sensitivity and 
Specificity) OR Mass Screening) 
 
157 
 
Search strategy Web of Science 
Search Query 
Items 
found 
#1 ((Acute phase protein) OR IP-10) AND Tuberculosis 126 
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eFigure 1. Risk of bias graph of included studies on C-reactive protein test. Each methodological quality item is 
presented as percentages across all included studies. The figure was generated using Review Manager Version 
5.3; Cochrane Collaboration. 
 
 
eFigure 2. Summary for risk of bias of included studies on C-reactive protein test. The green symbols represent 
low risk of bias, the yellow symbols represent unclear risk of bias, and the red symbols represent high risk of 
bias. The figure was generated using Review Manager Version 5.3; Cochrane Collaboration. 
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eTable 1. Positive Likelihood Ratio Summary. Diagnostic Random-Effects Model. 
Positive Likelihood Ratio - Model Results 
Estimate Lower bound Upper bound p-Value 
1.915 1.427 2.569 < 0.001 
Positive Likelihood Ratio - Heterogeneity 
tau^2 Q(df=13) Het. p-Value I^2 
0.282 357.507 < 0.001 96.364 
Positive Likelihood Ratio - Results (log scale) 
Estimate Lower bound Upper bound Std. error 
0.650 0.356 0.943 0.150 
 
 
eTable 2. Negative Likelihood Ratio Summary. Diagnostic Random-Effects Model. 
Negative Likelihood Ratio - Model Results 
Estimate Lower  bound Upper bound p-Value 
0.212 0.104 0.430 < 0.001 
Negative Likelihood Ratio - Heterogeneity 
tau^2   Q(df=13) Het. p-Value I^2 
1.795 2203.555 < 0.001 99.41 
Negative Likelihood Ratio - Results (log scale) 
Estimate Lower bound Upper bound Std. error 
-1.552 -2.261 -0.843 0.362 
 
 
eTable 3. Odds Ratio Summary. Diagnostic Random-Effects Model. 
Odds Ratio - Model Results 
Estimate Lower bound Upper bound p-Value  
8.270 3.404 20.090 < 0.001  
Odds Ratio - Heterogeneity 
tau^2 Q(df=13) Het. p-Value I^2  
2.410 131.054 < 0.001 90.08  
Odds Ratio - Results (log scale) 
Estimate Lower bound Upper bound Std. error  
2.113 1.225 3.000 0.453  
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eFigure 6. Risk of bias graph of included studies on IP-10 test. Each methodological quality item is presented as 
percentages across all included studies. The figure was generated using Review Manager Version 5.3; Cochrane 
Collaboration. 
 
 
 
 
eFigure 7. Summary for risk of bias of included studies on IP-10 test. The green symbols represent low risk of 
bias, the yellow symbols represent unclear risk of bias, and the red symbols represent high risk of bias. The 
figure was generated using Review Manager Version 5.3; Cochrane Collaboration. 
 
 
 
